|
Cyplasin-SC™ shows proof of efficacy in tumor bearing animals Edmonton, Alberta, October 12, 2007 CYPL: OTCBB, Frankfurt Exchange WKN:XYIA Cyplasin-SC™ has shown to be an efficient killer of many tumor cell lines in the laboratory. In previous animal dose ranging studies performed by AURIGON Life Sciences, Tutzing, Germany, it was shown that injection of Cyplasin-SC into healthy mice at high doses did not demonstrate any negative effects, and the animals remained unharmed. The same company then proceeded with experiments in order to determine if Cyplasin-SC has efficacy against tumors in animals. A specific strain of lab mouse having an impaired immune system was injected with human melanoma cells. These mice subsequently developed melanoma tumors having a high resemblance to the real life situation of a natural tumor in an animal and the tumors were allowed to grow until they had reached a considerable size. Cyplasin-SC™ was injected in the vicinity of the tumor, either in a high dose, or with half of that concentration or with the same solution having no Cyplasin-SC added (control solution). Injections were repeated every third day for 30 days consecutively with the tumor sizes being measured each time. In order to overcome individual differences, more than 100 mice were involved in the experiments. The final results showed that in those control mice which were injected with the control solution the tumor reached such a large size that the animals had to be sacrificed at the end of the experimental period. Mice receiving either the high dose or the half dose of Cyplasin-SC™ saw the growth of their tumors being arrested soon after the beginning of treatment. Mice which were given the highest dose of Cyplasin-SC saw their tumors sizes being half the size of the tumors as compared to those mice which were treated with the lower Cyplasin-SC concentration. “The data derived from these experiments are fundamental for the further development of Cyplasin-SC as an efficient tumor drug”, said Professor Christian Petzelt, CSO of Cyplasin Biomedical Ltd. “First, they demonstrate the efficacy of Cyplasin-SC for treating human melanoma, and second, they show the clear dose dependency of the drug. As required by Good Laboratory Practice Guide lines (GLP), all these experiments will now be repeated.” After their successful completion, the development of Cyplasin-SC™ will move into the animal toxicology testing phase before IND submission and the resultant initiation of phase I, experiments involving humans. About Melanoma Market statistics for skin cancer and melanoma show that melanoma currently affects more then 2.4 million people worldwide. In the US more than 62,000 new cases are reported every year, as fair-skinned and Sunbelt populations are at high risk for the disease. Australia has the highest rate of melanoma in the world among males and has the second highest rate in the world among females (Australia’s Health 2004, AIHW). Overall the world wide incidence has doubled over the past 20 years. About Cyplasin-SC™ In laboratory tests Cyplasin-SC™ has demonstrated a selective ability to rapidly kill melanoma cancer cells while leaving normal non-cancerous cells untouched. In animal efficacy studies Cyplasin-SC has demonstrated efficacy for melanoma in a dose related response. Cyplasin is a protein originally discovered and isolated by Professor Petzelt from a marine organism, the sea hare (Aplysia punctata). The protein is manufactured as a recombinant protein which allows the company to develop the protein as a potential anticancer therapeutic product. Patents have been issued to the Company covering the Cyplasin protein. About Cyplasin Biomedical Ltd. (CBL) Founded in 2007 and headquartered in Edmonton, Alberta, Canada with a research laboratory close to Berlin, Germany, CBL is dedicated to bringing new anticancer therapeutics to the marketplace. The Company’s current goal is to develop and commercialize the anticancer properties of Cyplasin-SC™ for skin cancers and melanomas. CBL is publicly traded (CYPL: OTCBB) Forward-Looking Statements This Press release includes and is based, inter alia, on forward-looking information and statements that are subject to risks and uncertainties that could cause actual results to differ. Such forward-looking information and statements are based without limitation, as statements regarding future drug development activities, anticipated products, or anticipated future revenues, benefits or advantages, and the future plans and objectives of the Company, that involve inherent risks and uncertainties and are subject to factors, many of which are beyond the Company's control, such as market acceptance of new products and services, changes in governmental regulations, interest rates, fluctuations in currency exchange rates and such other factors as may be discussed from time to time that may cause actual results or performance to differ materially from those currently anticipated in such statements. These expectations, estimates and projections are generally identifiable by statements containing words such as "expects", "believes", "estimates" or similar expressions. Although Cyplasin Biomedical Ltd., believes that its expectations and the information in this Press release were based upon reasonable assumptions at the time when they were made, it can give no assurance that those expectations will be achieved or that the actual results will be as set out in this Press release. Cyplasin Biomedical Ltd., makes no representation or warranty, expressed or implied, as to the accuracy, reliability or completeness of the information in the Press release, and neither Cyplasin Biomedical nor any of their directors, officers or employees will have any liability to you or any other persons resulting from your use of the information in the Press release. The OTCBB Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of this news release. Contact: Garth Likes |